A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

Vaccine

Volumn 30, Issue 12, 2012, Pages 2098-2108

  Hoft, Daniel F ^a   Blazevic, Azra ^a   Stanley, Jaime ^a   Landry, Bernard ^b   Sizemore, Donata ^b   Kpamegan, Eloi ^b   Gearhart, Jacqueline ^b   Scott, Alison ^b   Kik, Sandra ^c   Pau, Maria G ^c   Goudsmit, Jaap ^c   McClain, J Bruce ^b   Sadoff, Jerald ^c  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b Aeras Global TB Vaccine Foundation   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Human immunity; Prime boosting strategies; TB vaccines

Indexed keywords

ADENOVIRUS VECTOR; AERAS 402; AG85A ANTIGEN; AG85B ANTIGEN; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MYCOBACTERIUM ANTIGEN; PERFORIN; PLACEBO; TB10.4 ANTIGEN; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FATIGUE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL COUNT; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUBERCULOSIS; VACCINATION;

ACYLTRANSFERASES; ADENOVIRUSES, HUMAN; ADULT; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; GENETIC VECTORS; HUMAN EXPERIMENTATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84857373334     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.048     Document Type: Article

References (43)

1. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of Tuberculosis: meta-analysis of the published literature. JAMA 1994, 271:698-702.
2. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of Bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
3. Vogels R., Zuijdgeest D., van R.R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77:8263-8271.
4. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75:4105-4115.
5. Pal P.G., Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992, 60:4781-4792.
6. Horwitz M.A., Lee B.E., Dillon B.J., Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995, 92:1530-1534.
7. Blander S.J., Horwitz M.A. Vaccination with the major secretory protein of Legionella pneumophila induces cell-mediated and protective immunity in a guinea pig model of Legionnaires' disease. J Exp Med 1989, 169:691-705.
8. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994, 62:2536-2544.
9. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996, 2:893-898.
10. Wiker H.G., Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992, 56:648-661.
11. Belisle J.T., Varalakshmi D.V., Sievert T., Takayama K., Brennan P.J., Besra G.S. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997, 276:1420-1422.
12. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853-13858.
13. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71:1672-1679.
14. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002, 70:5446-5453.
15. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
16. + T cells in adults. Amer J Resp Crit Care Med 2010, 181:1407-1417.
17. + T-cell response in patients with pulmonary tuberculosis. Genes Immun 2007, 8:334-343.
18. Tholen DW, Linnet K, Kondratovich M, Armbruster DA, Garrett PE, Jones RL, et al. Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved guideline. NCCLS document EP17-A. Vol. 24, No. 34; 2004. http://www.clsi.org/source/orders/free/ep17-a.pdf.
19. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
20. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 2005, 73:4676-4683.
21. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
22. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
23. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
24. Wangoo A., Sparer T., Brown I.N., Snewin V.A., Janssen R., Thole J., et al. Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 2001, 166:3432-3439.
25. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., et al. A Mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. New Engl J Med 1996, 335:1941-1949.
26. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992, 89:12013-12017.
27. Bloom B.R., Flynn J., McDonough K., Kress Y., Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 1994, 191:526-536.
28. + T cells. Eur J Immunol 2000, 30:3689-3698.
29. + T cells in human tuberculosis. Proc Natl Acad Sci USA 2000, 97:12210-12215.
30. Ladel C.H., Daugelat S., Kaufmann S.H. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 1995, 25:377-384.
31. + T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guerin. J Infect Dis 2000, 181:1846-1849.
32. Rock K.L., Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005, 207:166-183.
33. Cresswell P., Ackerman A.L., Giodini A., Peaper D.R., Wearsch P.A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005, 207:145-157.
34. Bevan M.J. Cross-priming. Nat Immunol 2006, 7:363-655.
35. Lalvani A., Brooks R., Wilkinson R., Malin A.S., Pathan A.A., Andersen P., et al. Human cytolytic and interferon (-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998, 95:270-275.
36. + T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. J Immunol 2000, 165:925-930.
37. + T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med 1998, 187:1633-1640.
38. Stenger S., Hanson D.A., Teitlbaum R., Dewan P., Niazi K.R., Froelich C.J., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
39. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
40. Yewdell J.W., Nicchitta C.V. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 2006, 27:368-373.
41. + T cells. J Exp Med 2001, 194:1711-1719.
42. Campbell J.J., Murphy K.E., Kunkel E.J., Brightling C.E., Soler D., Shen Z., et al. CCR7 expression and memory T cell diversity in humans. J Immunol 2001, 166:877-884.
43. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.